Hyaluronan-based scaffolds (Hyalograft® C) in the treatment of knee cartilage defects: Preliminary clinical findings

Alessandra Pavesio, Giovanni Abatangelo, Anna Borrione, Domenico Brocchetta, Anthony P. Hollander, Elizaveta Kon, Francesca Torasso, Stefano Zanasi, Maurilio Marcacci

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Hyalograft® C is an innovative tissue-engineering approach for the treatment of knee cartilage defects involving the implantation of laboratory expanded autologous chondrocytes grown on a three-dimensional hyaluronan-based scaffold. This technique has recently been introduced into clinical practice, with more than 600 patients treated so far. Because no periosteal coverage is required to keep the graft in place, surgical time and morbidity are reduced, and handling of the graft is much simpler than currently available autologous chondrocyte implantation techniques. The safety profile of the treatment appears positive, with a limited number of adverse events reported. Here we discuss the clinical, arthroscopic and histological results from a cohort of 67 patients treated with Hyalograft® C (mean follow-up time from implantation of 17.5 months). Results are reported based on four endpoints: patients' subjective evaluation of knee conditions (97% of patients improved) and quality of life (94% improved), surgeons' knee functional test (87% of patients with the best scores), arthroscopic evaluation of cartilage repair (96.7% biologically acceptable) and histological assessment of the grafted site (majority of specimens hyaline-like). The positive clinical results obtained indicate that Hyalograft® C may be a viable therapeutic option for the treatment of acute cartilage lesions.

Original languageEnglish
Title of host publicationNovartis Foundation Symposium
Pages203-217
Number of pages15
Volume249
Publication statusPublished - 2003

Publication series

NameNovartis Foundation Symposium
Volume249

Fingerprint

Hyaluronic Acid
Cartilage
Knee
Chondrocytes
Transplants
Therapeutics
Hyalin
Tissue Engineering
Operative Time
Quality of Life
Morbidity
Safety

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Pavesio, A., Abatangelo, G., Borrione, A., Brocchetta, D., Hollander, A. P., Kon, E., ... Marcacci, M. (2003). Hyaluronan-based scaffolds (Hyalograft® C) in the treatment of knee cartilage defects: Preliminary clinical findings. In Novartis Foundation Symposium (Vol. 249, pp. 203-217). (Novartis Foundation Symposium; Vol. 249).

Hyaluronan-based scaffolds (Hyalograft® C) in the treatment of knee cartilage defects : Preliminary clinical findings. / Pavesio, Alessandra; Abatangelo, Giovanni; Borrione, Anna; Brocchetta, Domenico; Hollander, Anthony P.; Kon, Elizaveta; Torasso, Francesca; Zanasi, Stefano; Marcacci, Maurilio.

Novartis Foundation Symposium. Vol. 249 2003. p. 203-217 (Novartis Foundation Symposium; Vol. 249).

Research output: Chapter in Book/Report/Conference proceedingChapter

Pavesio, A, Abatangelo, G, Borrione, A, Brocchetta, D, Hollander, AP, Kon, E, Torasso, F, Zanasi, S & Marcacci, M 2003, Hyaluronan-based scaffolds (Hyalograft® C) in the treatment of knee cartilage defects: Preliminary clinical findings. in Novartis Foundation Symposium. vol. 249, Novartis Foundation Symposium, vol. 249, pp. 203-217.
Pavesio A, Abatangelo G, Borrione A, Brocchetta D, Hollander AP, Kon E et al. Hyaluronan-based scaffolds (Hyalograft® C) in the treatment of knee cartilage defects: Preliminary clinical findings. In Novartis Foundation Symposium. Vol. 249. 2003. p. 203-217. (Novartis Foundation Symposium).
Pavesio, Alessandra ; Abatangelo, Giovanni ; Borrione, Anna ; Brocchetta, Domenico ; Hollander, Anthony P. ; Kon, Elizaveta ; Torasso, Francesca ; Zanasi, Stefano ; Marcacci, Maurilio. / Hyaluronan-based scaffolds (Hyalograft® C) in the treatment of knee cartilage defects : Preliminary clinical findings. Novartis Foundation Symposium. Vol. 249 2003. pp. 203-217 (Novartis Foundation Symposium).
@inbook{fb249a5ef32f4ebb987c55f31d2cbcdc,
title = "Hyaluronan-based scaffolds (Hyalograft{\circledR} C) in the treatment of knee cartilage defects: Preliminary clinical findings",
abstract = "Hyalograft{\circledR} C is an innovative tissue-engineering approach for the treatment of knee cartilage defects involving the implantation of laboratory expanded autologous chondrocytes grown on a three-dimensional hyaluronan-based scaffold. This technique has recently been introduced into clinical practice, with more than 600 patients treated so far. Because no periosteal coverage is required to keep the graft in place, surgical time and morbidity are reduced, and handling of the graft is much simpler than currently available autologous chondrocyte implantation techniques. The safety profile of the treatment appears positive, with a limited number of adverse events reported. Here we discuss the clinical, arthroscopic and histological results from a cohort of 67 patients treated with Hyalograft{\circledR} C (mean follow-up time from implantation of 17.5 months). Results are reported based on four endpoints: patients' subjective evaluation of knee conditions (97{\%} of patients improved) and quality of life (94{\%} improved), surgeons' knee functional test (87{\%} of patients with the best scores), arthroscopic evaluation of cartilage repair (96.7{\%} biologically acceptable) and histological assessment of the grafted site (majority of specimens hyaline-like). The positive clinical results obtained indicate that Hyalograft{\circledR} C may be a viable therapeutic option for the treatment of acute cartilage lesions.",
author = "Alessandra Pavesio and Giovanni Abatangelo and Anna Borrione and Domenico Brocchetta and Hollander, {Anthony P.} and Elizaveta Kon and Francesca Torasso and Stefano Zanasi and Maurilio Marcacci",
year = "2003",
language = "English",
volume = "249",
series = "Novartis Foundation Symposium",
pages = "203--217",
booktitle = "Novartis Foundation Symposium",

}

TY - CHAP

T1 - Hyaluronan-based scaffolds (Hyalograft® C) in the treatment of knee cartilage defects

T2 - Preliminary clinical findings

AU - Pavesio, Alessandra

AU - Abatangelo, Giovanni

AU - Borrione, Anna

AU - Brocchetta, Domenico

AU - Hollander, Anthony P.

AU - Kon, Elizaveta

AU - Torasso, Francesca

AU - Zanasi, Stefano

AU - Marcacci, Maurilio

PY - 2003

Y1 - 2003

N2 - Hyalograft® C is an innovative tissue-engineering approach for the treatment of knee cartilage defects involving the implantation of laboratory expanded autologous chondrocytes grown on a three-dimensional hyaluronan-based scaffold. This technique has recently been introduced into clinical practice, with more than 600 patients treated so far. Because no periosteal coverage is required to keep the graft in place, surgical time and morbidity are reduced, and handling of the graft is much simpler than currently available autologous chondrocyte implantation techniques. The safety profile of the treatment appears positive, with a limited number of adverse events reported. Here we discuss the clinical, arthroscopic and histological results from a cohort of 67 patients treated with Hyalograft® C (mean follow-up time from implantation of 17.5 months). Results are reported based on four endpoints: patients' subjective evaluation of knee conditions (97% of patients improved) and quality of life (94% improved), surgeons' knee functional test (87% of patients with the best scores), arthroscopic evaluation of cartilage repair (96.7% biologically acceptable) and histological assessment of the grafted site (majority of specimens hyaline-like). The positive clinical results obtained indicate that Hyalograft® C may be a viable therapeutic option for the treatment of acute cartilage lesions.

AB - Hyalograft® C is an innovative tissue-engineering approach for the treatment of knee cartilage defects involving the implantation of laboratory expanded autologous chondrocytes grown on a three-dimensional hyaluronan-based scaffold. This technique has recently been introduced into clinical practice, with more than 600 patients treated so far. Because no periosteal coverage is required to keep the graft in place, surgical time and morbidity are reduced, and handling of the graft is much simpler than currently available autologous chondrocyte implantation techniques. The safety profile of the treatment appears positive, with a limited number of adverse events reported. Here we discuss the clinical, arthroscopic and histological results from a cohort of 67 patients treated with Hyalograft® C (mean follow-up time from implantation of 17.5 months). Results are reported based on four endpoints: patients' subjective evaluation of knee conditions (97% of patients improved) and quality of life (94% improved), surgeons' knee functional test (87% of patients with the best scores), arthroscopic evaluation of cartilage repair (96.7% biologically acceptable) and histological assessment of the grafted site (majority of specimens hyaline-like). The positive clinical results obtained indicate that Hyalograft® C may be a viable therapeutic option for the treatment of acute cartilage lesions.

UR - http://www.scopus.com/inward/record.url?scp=0038619071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038619071&partnerID=8YFLogxK

M3 - Chapter

C2 - 12708658

AN - SCOPUS:0038619071

VL - 249

T3 - Novartis Foundation Symposium

SP - 203

EP - 217

BT - Novartis Foundation Symposium

ER -